
You are here
Consultations
We conduct public consultations as part of our broader stakeholder engagement work, including on changes to regulatory requirements or practices, reviews of business processes, standards or guidelines, and TGA fees and charges.
Filters
Status
Categories
- Advertising (2) Apply Advertising filter
- Australian Register of Therapeutic Goods (ARTG) (1) Apply Australian Register of Therapeutic Goods (ARTG) filter
- Biologicals (2) Apply Biologicals filter
- Remove Blood and blood components filter Blood and blood components (0)
- Remove Complementary medicines filter Complementary medicines (7)
- Fees/Payments (1) Apply Fees/Payments filter
- Import/Export (1) Apply Import/Export filter
- Remove Labelling/Packaging filter Labelling/Packaging (1)
- Legislation (3) Apply Legislation filter
- Remove Listed medicines filter Listed medicines (2)
- Medical devices/IVDs (55) Apply Medical devices/IVDs filter
- Medical devices safety (1) Apply Medical devices safety filter
- Medicines (2) Apply Medicines filter
- Medicines safety (1) Apply Medicines safety filter
- OTC medicines (12) Apply OTC medicines filter
- Other therapeutic goods (1) Apply Other therapeutic goods filter
- Prescription medicines (5) Apply Prescription medicines filter
- Remove Safety of medicines & medical devices filter Safety of medicines & medical devices (0)
- Scheduling (55) Apply Scheduling filter
- Therapeutic Goods Administration (TGA) (2) Apply Therapeutic Goods Administration (TGA) filter
- Remove Therapeutic goods regulation filter Therapeutic goods regulation (2)
- (-) Remove Listed medicines filter Listed medicines
- (-) Remove Safety of medicines & medical devices filter Safety of medicines & medical devices
- (-) Remove Blood and blood components filter Blood and blood components
- (-) Remove Complementary medicines filter Complementary medicines
- (-) Remove Therapeutic goods regulation filter Therapeutic goods regulation
- (-) Remove Labelling/Packaging filter Labelling/Packaging
Proposed update to the evidence guidelines for listed medicines
Closed on 1 April 2022
Proposed changes to the Permissible Ingredients Determination: Low-negligible risk changes 2021-22
Closed on 15 September 2021
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Methyl salicylate
Closed on 18 May 2021
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Lidocaine (lignocaine)
Closed on 18 May 2021
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Sedating antihistamines
Closed on 18 May 2021
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Menthol
Closed on 18 May 2021
Proposal to remove redundant processes for entering certain formulation information into a therapeutic goods application
Closed on 24 February 2021
Changes to permissible ingredients - Low-negligible risk
Closed on 11 October 2019
Proposed clarification that goods are therapeutic goods - goods containing folate substances in certain circumstances
Closed on 18 September 2019
Discontinuing pre-market evaluation of Herbal Component Names (HCNs)
Closed on 12 January 2018